Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia

Ono Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Community-acquired Pneumonia

Treatments: Drug: ONO-5046Na

Study type: Interventional

Funder types: Industry

Identifiers

NCT00417326

ONO-5046Na-14

Details and patient eligibility

About

The purpose of this study is to determine the safety and efficacy of ONO-5046Na in patients with acute respiratory failure associated with community-acquired pneumonia

Enrollment: 174 patients

Sex: All

Ages: 20 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with community-acquired pneumonia
• Patients with acute respiratory failure

Exclusion criteria

• Patients with nosocomial pneumonia
• Patients on mechanical ventilation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

174 participants in 2 patient groups, including a placebo group

P

Placebo Comparator group

Treatment:

Drug: ONO-5046Na

Drug: ONO-5046Na

E

Experimental group

Treatment:

Drug: ONO-5046Na

Drug: ONO-5046Na